SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-008630 to MeiraGTx Holdings plc (MGTX) (CIK 0001735438) (MGTX)

MeiraGTx Holdings plc (MGTX) (CIK 0001735438)
Date: Aug. 8, 2023 · CIK: 0001735438 · Accession: 0000000000-23-008630

Regulatory Compliance Offering / Registration Process Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-273675

Date
August 8, 2023
Author
Alexandria Forbes, Ph.D.
Form
UPLOAD
Company
MeiraGTx Holdings plc (MGTX) (CIK 0001735438)

Letter

United States securities and exchange commission logo August 8, 2023 Alexandria Forbes, Ph.D. President and Chief Executive Officer MeiraGTx Holdings plc 450 East 29th Street, 14th Floor New York, New York 10016 Re:MeiraGTx Holdings plc Registration Statement on Form S-3 Filed August 3, 2023 File No. 333-273675 Dear Alexandria Forbes: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Keith Halverstam

Show Raw Text
United States securities and exchange commission logo
August 8, 2023
Alexandria Forbes, Ph.D.
President and Chief Executive Officer
MeiraGTx Holdings plc
450 East 29th Street, 14th Floor
New York, New York 10016
Re:MeiraGTx Holdings plc
Registration Statement on Form S-3
Filed August 3, 2023
File No. 333-273675
Dear Alexandria Forbes:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Keith Halverstam